Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 23 for “"Pramipexole"”.
-
Behavioral Mechanisms of Pramipexole-Induced Impulsivity: Discrimination Processes Underlying Decision-Making
… in humans and nonhumans alike. For instance, pramipexole, a dopamine agonist medication prescribed for Parkinson’s disease, has been associated with reports of increased rates of impulsive behavior. By which behavioral mechanisms pramipexole achieves these effects is unknown and requires …
-
Transdermal delivery of pramipexole using microneedle technology for the potential treatment of Parkinson’s disease
… for dopamine production within the brain. Pramipexole (PRA) is a dopamine agonist that enhances dopamine neurotransmission, restoring balance and alleviating symptoms. The work presented here shows how transdermal drug delivery, using microneedle (MN) technology, is a promising avenue for …
-
Effects of acute pramipexole on preference for gambling-like schedules in male Wistar rats
In recent years, pramipexole and other direct-acting dopamine agonist medications have been implicated in the development of impulsive behaviors such as pathological gambling in patients with Parkinson's disease. Despite the significance of these clinical findings, experimental evaluations of …
-
Influence of Pramipexole on Probability Discounting and Ventral Pallidal Function: Assessments in Parkinsonian-Like Rats
… the time this dissertation was being developed, pramipexole was the drug, gambling was the behavior, and Parkinson's disease (PD) was the pathology most widely reported for this phenomenon. Therefore, we first developed a behavioral paradigm (i.e., probability discounting) to measure risk-taking, …
-
An experimental medicine investigation of the effects of potential novel antidepressant interventions on emotion and reward related information processing
… the dopamine D2/D3 receptor-preferring agonist pramipexole. In addition to their effects on hot cognitive processes, for each of these interventions, potential effects on subjective state and, where of interest, also effects on other relevant measures (e.g. HPA axis activity for practising …
-
Impacts of reward schedules and a dopamine agonist on dopamine receptor expression in an animal model of gambling addiction
… with the addition of a dopamine agonist, pramipexole in follow-up experiments. Rats that were trained on the random ratio schedule were highly motivated but did not exhibit other signs of addiction. When pramipexole was added, rats displayed additional addiction-like symptoms and their …
-
50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs as a possible behavioral marker of the affective properties of dopamine-replacing therapy in Parkinson's disease
… (L-DOPA, 6 or 12 mg/kg, i.p.), or pramipexole (2 or 4 mg/kg, i.p.) were administered in a test cage (× 5 administrations) on alternate days. Seven days after treatment discontinuation, rats were re-exposed to the test cage to measure conditioned calling behavior and thereafter …
-
Linking reward-learning and affect in health and depression
… imaging; fMRI) data to investigate the effect of Pramipexole, a promising antidepressant, on behavioural and neural reward learning. The results of this study are reported in chapters 2 and 3. In chapter 2, I report on the behavioural findings from this study: Pramipexole specifically increases …
-
Reciprocal Interactions Between Monoamines as a Basis for the Antidepressant Response Potential
… with distinctive pharmacological properties (pramipexole, aripiprazole, and quetiapine) on function of the monoaminergic systems involved in the pathophysiology and treatment of MDD. Reciprocal interactions between the monoamines serotonin, norepinephrine, and dopamine systems allow the drugs …
-
Pharmacotherapies in Parkinson Disease: Investigating Trends and Adverse Health Outcomes
… levodopa toxicity, pergolide withdrawal, and pramipexole label revisions; 2) heart failure was the only adverse cardiovascular or cerebrovascular outcome that demonstrated a significant association with non-ergot DA use, mainly pramipexole; and 3) anticholinergic burden in PD was associated …
-
ENZYMES FROM MARINE MICROORGANISMS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE MOLECULES
… Biotransformation substrate range included pramipexole, as main target, but it also embraces other common building blocks for synthetic industrial preparation. The stereoselective reduction of structurally different ketones using halotolerant marine yeasts (Meyerozyma guilliermondii and …
-
Investigating motivation and apathy-related behaviour using effort-based tasks
… disorders associated with apathy; escitalopram, pramipexole and donepezil, were tested acutely in the EBF task. Escitalopram and pramipexole reduced shuttling behaviour, and donepezil reduced proportion of material shuttled but only at the lowest dose, suggesting these treatments may reduce …
-
Ανάπτυξη μεθόδων προσδιορισμού φαρμάκων με την τεχνική LC-MS για μελέτες βιοϊσοδυναμίας
… of a new method for the determination of drug pramipexole (PPX) in plasma. Pramipexole is included among the most important drug substances against Parkinson’s disease. The new method appeared to be equivalent regarding the sensitivity with already published studies that use more expensive …
-
Aminergic systems in sleep disorders of neurological diseases
… after administration of a dopamine agonist drug, Pramipexole 0.18 mg). In both recordings, PLMS and epileptiform discharges were also counted and analysed. RESULTS: Eighty-five patients who had been previously diagnosed with Epilepsy met the inclusion criteria for this study. Of these, 17/85 (20%) …
-
Behavioural investigation into whether L-DOPA, the current 'gold standard' pharmacotherapy for Parkinson’s disease can be improved by optimising its treatment strategies
… L-‐DOPA combined with the dopamine agonist pramipexole resulted in improved motor function and a reduction of dyskinesia.<br/>In conclusion, manipulating L-‐DOPA treatment strategies can improve motor<br/>function while reducing dyskinesia expression. These results suggest …
-
Deciphering the Mechanisms Underlying Metabolic Dysregulation in ALS
… of TDP-43G298S, and we find that treatment with pramipexole, a dopamine agonist, improves locomotor function in Drosophila models of TDP-43 proteinopathy. Next, in Chapter 2.3, we show that overexpression of the rate limiting enzyme of glycolysis, Phosphofructokinase (PFK), mitigates TDP-43 …
-
Investigating the Dopaminergic and Glucocorticoid Systems as Underlying Mechanisms of Anhedonia
… induced DA activation, and reduced following pramipexole- (PRAMI) induced DA inhibition. Additionally, a 21-day chronic mild stress (CMS) regimen attenuated the response bias in a subpopulation of animals relative to no stress controls. Finally, the glucocorticoid antagonist, mifepristone …
-
SPINAL CORD REFLEXES IN A BRAIN-IRON DEFICIENT MODEL OF RESTLESS LEGS SYNDROME: ROLE OF DOPAMINE AND ADENOSINE RECEPTORS
… of this model to dopamine receptor modulators Pramipexole (PPX, D3 receptor agonist, 0.5 mg/kg, i.p.) and SCH 39166 (Ecopipam, D1 receptor antagonist, 0.5 mg/kg + 1.0 mg/kg, i.p.), and adenosine receptor modulators caffeine (A1R/A2R, 50 mg/kg, i.p.) and N6-cyclpentyladenosine (CPA, A1R agonist, …
-
CENTRAL SENSORIMOTOR CHANGES DUE TO PERIPHERAL NERVE INJURY: ROLE OF DOPAMINERGICS AND OPIOIDS
… of a dopamine (DA) D3 receptor agonist, pramipexole (PPX), with morphine achieved analgesia in in a centrally induced model of CNP. Here we used a more clinically relevant disease of peripherally induced CNP (sciatic nerve ligation, SNL) to test if this treatment would be more effective …
-
Meccanismo d'azione del Pramipexolo nella terapia della malattia di Parkinson
Pramipexole (PPX) is a dopamine (DA) D3 and D2 receptors agonist widely used alone or in combination with levodopa as Dopamine Replacement Therapy in Parkinson’s disease. In clinical and preclinical studies, PPX improved motor deficits, this evidence led to lowering daily dose of levodopa, delaying …
Page 1 of 2